[Webinar] How to better optimize an oncology drug discovery program
Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.Read more
For Oncodesign, artificial intelligence (AI) is not a goal, but rather a powerful technology to make drug discovery faster and more reliable.
AI is the technological pillar chosen by Oncodesign to generate its innovation and support its growth over the next 5 to 10 years. We are committed to bringing therapeutic innovation to patients at an ever faster pace.
The main objective of the Artificial Intelligence Business Unit is to develop a platform to identify and validate therapeutic targets. The therapeutic target is the cornerstone of Drug Discovery programs in Precision Medicine. This platform, created within Oncodesign, is strategic in order to fulfill its goals.
This technology platform was designed to identify signatures that can stratify populations of patients refractory to anticancer drugs. These signatures are then translated into therapeutic targets by biologists in our laboratories.
A joint laboratory, the AIDD4H "LabCom", is run in collaboration with the CIAD [French Distributed Knowledge and Artificial Intelligence laboratory] for an alliance of connectionist and symbolic AI technologies.
Oncodesign selected the best AI technologies and chose to work in collaboration with the best experts from other professions in the drug discovery process by creating the FederAIdd Open Campus.
Deploy AI technologies to advance your discoveries: Oncodesign supports you through our Services, partnerships or licensing offers.
Our AI BU team is made up of highly qualified scientists with all the different expertise needed to mobilize artificial intelligence at every stage of the drug discovery process.Our activities rely on a team of data scientists, bioinformaticians, mathematicians, data hunter et architects, statisticians, biologists, pharmacologists, chemists,supported by the Oncodesign IT department to run a high-performance and secure storage and calculation infrastructure.
Come back regularly to check if there is a meeting nearby your place to meet one of our experts in both AI & Drug Discovery.
Early/ late resistance marker; Immunological profile; NGS; Non small-cell lung cancer; Pancreatic ductal adenocarcinoma; Triple negative breast or Luminal Breast Cancer.
EHDEN network will enable transparent & fully reproducible research by standardizing both the health data & the analytical pipeline.